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background. No information is available about the financial impact of central venous catheter (CVC)–associated bloodstream infection
(BSI) in Mexico.
objective. To calculate the costs associated with BSI in intensive care units (ICUs) in Mexico City.
design. An 18-month (June 2002 through November 2003), prospective, nested case-control study of patients with and patients without BSI.
setting. Adult ICUs in 3 hospitals in Mexico City.
patients and methods. A total of 55 patients with BSI (case patients) and 55 patients without BSI (control patients) were compared
with respect to hospital, type of ICU, year of hospital admission, length of ICU stay, sex, age, and mean severity of illness score. Information
about the length of ICU stay was obtained prospectively during daily rounds. The daily cost of ICU stay was provided by the finance
department of each hospital. The cost of antibiotics prescribed for BSI was provided by the hospitals’ pharmacy departments.
results. For case patients, the mean extra length of stay was 6.1 days, the mean extra cost of antibiotics was $598, the mean extra
hospital cost was $11,591, and the attributable extra mortality was 20%.
conclusions. In this study, the duration of ICU stay for patients with central venous catheter–associated BSI was significantly longer
than that for control patients, resulting in increased healthcare costs and a higher attributable mortality. These conclusions support the
need to implement preventive measures for hospitalized patients with central venous catheters in Mexico.
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Bloodstream infection (BSI) is a major cause of mortality
among critically ill patients.1-10 The presence of a central ve-
nous catheter (CVC) is a major risk factor for the develop-
ment of BSI.4,11-13 Several studies have demonstrated that
CVC-associated BSIs are associated with an extended hos-
pitalization duration and increased patient morbidity.5,14 One
important means of reducing CVC-associated BSI in Latin
America and elsewhere has been implementation of infection
control programs that emphasize improved hand hygiene
adherence,15,16 improved care of the catheter-insertion site,17-23
and use of antimicrobial agent–impregnated catheters.24 We
report the findings of a prospective, multicenter, nested,
matched case-control study that assessed attributable extra
length of stay (LOS), antibiotic use, costs, and mortality
among patients with CVC-associated BSI who were hospi-
talized in intensive care units (ICUs) in Mexico City.
methods
Setting
The study was conducted in 3 hospitals in Mexico City. Each
center had an infection control team comprising an internal
medicine physician with formal education in infectious dis-
eases and an infection control nurse.25
General Hospital (hospital A) is a public 1,100-bed hos-
pital; Specialties Instituto Mexicano del Seguro Social (IMSS)
Hospital (hospital B) and Gabriel Mancera IMSS Hospital
(hospital C) are social-security hospitals of 600 beds and 400
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table 1. Baseline Characteristics of Intensive Care Unit (ICU) Patients in Mexico







(n p 55) P
Mean length of stay x5 d 55 (100) 55 (100) 1.99
Mean age, y 46.22 43.69 .43
Male sex 25 (45) 25 (45) 1.99
Admitted to medical or surgical ICU 55 (100) 55 (100) 1.99
Mean severity of illness score 3.98 3.49 .32
ICU type, hospital
Medical-surgical, General Hospital 26 26 1.99
Neurosurgical, General Hospital 16 16 1.99
Medical-surgical, Specialties IMSS Hospital 10 10 1.99
Medical-surgical, Gabriel Mancera IMSS Hospital 3 3 1.99
note. Data are no. (%) of patients, unless otherwise indicated. IMSS, Instituto Mexicano del
Seguro Social.
beds, respectively. The ICUs of the hospitals treat patients
who have had open heart surgery, neurosurgery, or ortho-
pedic surgery performed and patients who have a complicated
medical illness. The institutional review board at each center
approved the study protocol.
Study Population and CVC Practices
We included all patients admitted to the study ICUs during
the 18-month period from June 2002 through November
2003 who had had a CVC in place for at least 24 hours.
Patients at hospital A were admitted from June 2002 through
November 2003, patients at hospital B were admitted from
November 2002 through November 2003, and patients at
hospital C were admitted from April through November 2003.
Nontunneled, non–antimicrobial-impregnated CVCs were
inserted from the bedside by treating physicians after the skin
was prepared with povidone-iodine.
At the beginning of the surveillance period, measures to
improve healthcare worker compliance with hand washing,
care of CVC sites, and care of intravenous administration
sites were implemented. Measures comprised education, train-
ing, outcome surveillance, process surveillance, and perfor-
mance feedback.26
Nosocomial Infection Surveillance and Data Collection
All patients admitted to the hospital with a CVC-associated
BSI detected by prospective nosocomial surveillance were en-
rolled and included as case patients. An infection control
nurse at each study center collected data prospectively from
patient medical records. The study coordinator (V.D.R.)
trained the data collectors at each center before commence-
ment of the study. For each study patient, age and sex, hos-
pital, ICU type, mean severity of illness score, and LOS were
recorded. In addition, antibiotic consumption was recorded.
We followed the recommendations of a 1969 World Health
Organization European symposium on the consumption of
drugs. We also used the Anatomical Therapeutic Chemical
Classification system, which is a common classification system
for drug use, and the defined daily dose (DDD) was used as
the comparative unit of drug consumption.27 Active surveil-
lance for CVC-associated BSI was performed at each study
center, starting in June 2002 and finishing in November 2003.
Definitions
Centers for Disease Control and Prevention definitions were
used to define CVC-associated BSI as laboratory-confirmed
BSI or clinical primary nosocomial sepsis.28
Laboratory-confirmed BSI. To meet the criteria for labo-
ratory-confirmed BSI, the first criterion was recovery of a
recognized pathogen unrelated to infection at another body
site from one or more cultures of percutaneous blood. Com-
mon skin commensals (eg, diphtheroids, Bacillus species, Pro-
pionibacterium species, coagulase-negative staphylococci, and
micrococci) must have been recovered from 2 or more cul-
tures of blood specimens drawn on separate occasions. The
second criterion was the presence of at least 1 of the following
signs or symptoms unrelated to infection at another body
site: fever (temperature of greater than 38C [greater than
100.4F]), chills, and/or hypotension.
Clinical primary nosocomial sepsis. To meet the criteria
for clinical primary nosocomial sepsis, the presence of at least
1 of the following clinical signs unrelated to another recog-
nizable cause of infection was required: fever (temperature,
138C [1100.4F]), hypotension (systolic blood pressure, !90
mm Hg), and/or oliguria (urine output, !20 mL/h). However,
for these patients, blood cultures were either not performed
or did not yield pathogens, and no infection was apparent at
another body site. The physician recommended treatment for
sepsis.
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table 2. Studies in Which Central Venous Catheter–Associated
Bloodstream Infection Was Associated With Extra Costs
Study Country Extra cost, US$
Liu et al.35 Taiwan 66,302
Orsi et al.14 Italy 21,612
Pittet et al.5 United States 29,000
Elward et al.36 United States 39,219
Payne et al.37 United States 5,875
Rosenthal et al.10 Argentina 4,888
Culture Techniques
The patients’ attending physicians independently decided
whether to perform cultures of catheters and blood cultures.
We used the semiquantitative culture method for identifying
organisms from catheter culture,29 and results were compared
with organisms isolated from blood culture, when available.
Specimens not immediately cultured were refrigerated at 4C.
All cultures were inoculated with specimens within 8 hours
of catheter removal. Standard laboratory methods were used
to identify microorganisms in blood and catheter cultures.29-31
Selection and Matching of Case and Control Patients
To conduct the study, we analyzed patients with CVC-asso-
ciated BSI (case patients) and patients without CVC-associ-
ated BSI (control patients) who were hospitalized for at least
5 days in the facility to which they were admitted. ICU type,
year of admission to the ICU, LOS, sex, age, and mean severity
of illness score were recorded.32 Each case patient was matched
to one control patient.33
Cost Estimation
The duration of ICU stay was obtained prospectively for each
patient, and the number of ICU bed–days were used as a
proxy for fixed costs of ICU stay. Current expenditures on
fixed costs were used to convert the number of ICU bed–
days into US dollars. DDDs34 and their associated market
prices were provided by the hospitals’ pharmacy departments.
The consumption of all other resources that reflect variable
costs (ie, cash expenditures) were obtained from each study
center’s finance department, and the relevant market price
was assumed to reflect opportunity costs. The extra cost at-
tributable to BSI was defined as the median difference in
variable costs (ie, cash expenditures) and LOS between case
patients and their matched control patients. A monetary val-
uation of the opportunity costs of the ICU bed–days lost to
BSI was also made.
Outcomes
The primary outcome effects evaluated in this study included
additional days of hospitalization, extra costs, and attributable
mortality of CVC-associated BSI.
Statistical Analysis
Epi Info statistical software, version 6.04b (Centers for Dis-
ease Control and Prevention), was used to perform the data
analysis. The x2 analysis (for dichotomous variables) and the
Student t test (for continuous variables) were used to analyze
baseline differences between treatment groups. When appro-
priate, the Fisher exact test was used. Relative risk ratios, 95%
confidence intervals, and P values were assessed for all pri-
mary and secondary outcomes.
results
During the study period (June 2002 through November
2003), 1,615 adult patients were admitted to the study ICUs;
172 (10.6%) of these patients developed a CVC-associated
BSI (22 [40%] had laboratory-confirmed BSI, and 33 [60%]
had clinical sepsis). Fifty-five (31.9%) of the 172 patients had
a LOS of 5 days or more and were included in the study.
Fifty-five control patients were matched with case patients on
the basis of a LOS longer than 5 days, hospital, ICU type,
sex, age, and mean severity of illness score. Baseline char-
acteristics were not different between case and control pa-
tients (Table 1).
The cumulative number of ICU bed–days was 739 for case
patients and 406 for control patients. The mean number of
ICU-days was 13.4 for case patients and 7.34 days for control
patients. The cumulative number of extra ICU bed–days for
case patients was 333, with a mean excess LOS of 6.05 days
per case patient (Table 2). Each ICU bed–day lost to BSI was
assumed to be worth $1,200, on the basis of data provided
by the finance department of each hospital. This finding im-
plies that the value of the 333 lost bed-days in terms of
alternative use was $579,133, or $7,260 per BSI case (Table
2). The additional costs of antibiotics were $32,912, or $598
per case patient; the additional value of the remaining variable
costs was $146,622, or $2,666 per BSI case. The total costs
were $1,593,149 for case patients and $955,648 for control
patients, for a difference of $637,501, or $11,591 per BSI case
(Table 2). Case patients were much more likely to have re-
ceived antimicrobial therapy, with a mean of 10.3 extra an-
tibiotic DDDs (Table 2). Twenty-three case patients (41.8%)
and 12 control patients (21.8%) died, for an attributable mor-
tality due to CVC-associated BSI of 20.0% (relative risk, 1.92
[95% confidence interval, 0.95-3.85]; ).Pp .06
discussion
The presence of a CVC is a major risk factor for BSI.4,11-13
Critically ill patients often require extended use of CVCs and
have a high risk of developing a BSI.38,39 Increases of 4%-37%
in attributable mortality have been reported in several studies
of CVC-associated BSI,2,5,9,40,41 although this association has
not been a consistent finding.42,43
In our study, we found that CVC-associated BSI was related
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to a median excess costs of $11,591 and an extra LOS of 6.1
days per episode. In contrast, almost all studies that evaluated
the impact of CVC-associated BSI on patient outcomes have
found significantly increased healthcare costs and excess LOS
for patients who developed this type of nosocomial infection
(Table 2). The excess healthcare costs reported from devel-
oped countries are significantly higher than costs found in
our study5,7,14 and higher than costs reported from Argentina,
where the extra costs were reported to be $4,888.10
Our study may underestimate the true costs of CVC-as-
sociated BSI in other countries where expensive medical tech-
nologies not yet available in Mexico are routinely used. For
example, the mean cost per day of hospitalization in most
US centers is more than 5 times that in Mexico. Also, the
real attributable mortality might be higher in Mexico, because
patients whose care was prohibitively expensive might have
died early during their hospital stay. Notwithstanding these
possibilities, our data demonstrated that CVC-associated BSIs
significantly increased the cost of treatment for these patients.
Studies of nosocomial infection have revealed that the use
of antibiotics is increasing. Our study, for example, revealed
a mean of 10 additional antibiotic DDDs for patients with
CVC-associated BSI, which accounted for $589 of the mean
excess healthcare costs per episode. The excess use of anti-
biotics has important consequences for patients in the ICU
setting, for whom the risk of acquiring drug-resistant nos-
ocomial pathogens may be higher than that for patients hos-
pitalized in other settings.44 Thus, prevention of CVC-asso-
ciated BSI may reduce healthcare costs through reducing LOS,
antibiotic use, and the antibiotic pressure that is driving the
selection of resistant microorganisms in hospitals.45
Finally, our discoveries are concordant with those of other
studies that have found an increased mortality among patients
with CVC-associated BSI.2,5,9,40,41 It is possible that the 20%
attributable mortality found in this and other studies is an
artificial product of the measurement techniques used (ie,
mean severity of illness score or other severity of illness scores
calculated at ICU admission rather than at the moment of
onset of CVC-associated BSI).43 In our study, we were unable
to find statistically significant differences in mortality between
case and control patients. The main reason for this was prob-
ably our small sample size (55 case patients and 55 control
patients).
This study has a number of limitations. In Mexico, labo-
ratory resources are expensive and scarce, and frequently the
only BSI criterion we can use is the presence of clinical sepsis.
The number of matching variables used might not account
for all of the variation in LOS and cost outcomes. A weakness
of case-control studies is that it is only possible to match
subjects on the basis of a relatively small number of variables
before selection bias arises. The inability to measure severity
of illness scores on a daily basis in our study hospitals was
another limitation of our study. Future studies must use
more-rigorous analytic methods, such as time series analysis,46
to assess the true impact of CVC-associated BSI on mortality.
However, the preponderance of current evidence suggests that
CVC-associated BSI is associated with excess patient mor-
tality, and our data are consistent with this body of evidence.
Multifaceted programs developed for preventing CVC-as-
sociated BSI have proved to be useful. Examples of these
measures are rigorous hand washing compliance, improved
care of vascular catheter–insertion sites, judicious use of an-
timicrobial therapy, and use of antimicrobial-impregnated
catheters. Our data suggest that successful implementation of
such programs would not only significantly reduce patient
mortality but also result in considerable cost savings and re-
duced LOS.
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